Pharma withheld faulty device info in rivaroxaban trial

Patients must live with uncertainty until concerns over key trial data are addressed Related items fromOnMedica Extending anticoagulation duration cuts risk of VTE recurrence Metformin lowers cardiac deaths better than other drugs US doctor says FDA should have withdrawn rosuvastatin NICE calls for safer use of controlled drugs BMJ questions trial evidence for rivaroxaban
Source: OnMedica Latest News - Category: UK Health Source Type: news